CereScan on Forbes.com: Using Data Analytics to Fight the Opioid Crisis

The opioid crisis statistics are alarming: Drug overdoses, most of which are related to opioids, killed over 64,000 people in the United States last year — an increase of 21% over 2015. Disturbing as those numbers are, understanding the data behind opioid addiction, and analyzing the overwhelming information being collected is critical to fighting the drug crisis.

In the article title “Using Big Data Medical Analytics to Address the Opioid Crisis,” CereScan CEO, John Kelley, discusses how data analytics can and must become a key component in the effort to end the opioid epidemic.

“We’ve all seen the statistics: Drug overdoses, most of which are related to opioids, killed over 64,000 people in the United States last year — an increase of 21% over 2015, according to the CDC. The New York Times just reported that fentanyl has overtaken the top spot from heroin as the leading cause of these deaths. Almost as chilling, there are an estimated 2 million prescription opioid addicts, putting a squeeze on the economy to the tune of more than $75 billion annually.

The national opioid crisis is a dilemma of dichotomies. There are challenges with both prescription and illicit drugs. The solutions must consist of efforts that realistically can reduce the number of people who become addicts in the first place, as well as cure those who do…”

Read the full article on Forbes.com

 

Just Like Wine, No Two Brains are Alike

Most physicians I know believe in the health properties of wine when taken in moderation. It improves stress levels, lowers risk of stroke and, depending on the research you read, may even help with arterial sclerosis. If nothing else, it helps doctors relax and gives them something other than medicine to talk about.

Wine was central to my thesis when I recently participated in Singularity University’s Global Forum, a world-class collection of thinkers, leaders and doers who educate, influence and inspire other on the front lines of technical innovation. I was a member of the Breakthrough Panel, which included other leaders in neuroscience.

I used an analogy to show how, like the human brain, no two vintages of wine are the same but they do have similarities that connect them in a variety of ways. An experienced sommelier is trained to pick up on the subtle differences between wines, just like a physician is trained to identify the subtle differences between medical conditions.

Addressing the uniqueness and complexity in identifying abnormalities in the human brain, which has been greatly enhanced through the use of breakthrough technology and advanced data analytics, is much like addressing the subtleties of different wines. Instead of an aficionado using his or her trained nose and palate, doctors and other medical specialists need to apply new technologies to collect data about traumas, symptoms, imaging, genomics and more on one side, and help deliver faster and more accurate diagnoses for conditions ranging from Alzheimer’s to strokes.

I cited recent literature and use cases, showing the power of data in its objective measurement and predictive capabilities. Put simply, biomedical programs have a treasure trove of data that can be mined to assist in the identification of conditions and the subsequent prescription of therapies. because of big data analytics, physicians can know dramatically more about their patients and directly translate that knowledge into improved decision making and results.

The bottom line from the Global Forum is that collaboration and data sharing drives progress and innovation in the medical fields and beyond. For the wine lover, this means a future of good drinks and even better medicine.

John A. Kelley, Jr., is Chairman and CEO of CereScan, a functional brain diagnostics company headquartered in Denver.

 

CereScan in-network insurance

CereScan is Now In-Network With Anthem Blue Cross

Got you covered

We are proud to announce that all brain diagnostic services offered at CereScan’s Colorado location are now covered in-network by Anthem Blue Cross and all Blue Cross affiliates. It is now easier than ever to get the answers that you or a loved one deserve.

At CereScan, it’s important for us to make our brain diagnostic services available to those who need them. That’s why we will be continuing to expand our in-network coverage. If you currently have insurance that isn’t in-network, it could be soon.

If you have not found answers to your concerns and are still interested in how this diagnostic information might be life changing, please contact us using our toll-free number (866) 722-4806, or fill out our contact form.  

We work with variety of health insurance plans and can help determine if your current insurance policy may cover this procedure.  No-interest payment plans are available if insurance is not an option.

Non-Colorado residents can also take advantage of in-network coverage! Call today to speak to our one of our patient care coordinators to learn how.

Phone Number: 866-722-4806

Email: pcc@cerescan.com

John Kelley CEO of CereScan

CereScan’s Kelley To Share His Unique Insights Into Unlocking The Mysteries Of The Human Brain As Panelist At Singularity University’s Global Forum

John Kelley, Chairman and CEO of CereScan®, will inject his inimitable style and passion for the plight of sufferers of chronic brain disorders when he addresses Singularity University’s Global Forum as a member of the Breakthrough Braintech Panel on August 15, 2017 in San Francisco. Kelley will join other innovators in discussing the connection between our biology and our inner selves and finding ways to exponentially improve our mental health.

The Global Forum is Singularity University’s flagship event and boasts a world-class collection of thinkers, leaders and doers who have come together to educate, influence and inspire others on the front lines of technical innovation.

“The chance to meet and collaborate with so many individuals who are trailblazers and barrier busters in the fields of technology and mental health is certainly my honor and privilege,” said Kelley. “The Global Forum provides a unique opportunity for us front line warriors to exchange ideas on emerging technologies and help change the direction and pace of global health.”

Featured prominently in Kelley’s presentation is CereScan’s recently unveiled CereMetrix® data analytics platform, which provides decision support and cohort analysis to medical professionals and researchers involved in diagnosing and identifying abnormalities in the human brain. CereMetrix® is a multi-variable search engine and correlative tool to support research and diagnostic applications. Through its patented neuroimaging database systems and methods, the platform is designed to accelerate the accurate and effective diagnosis of complex brain-related disorders, improving treatment and outcomes for patients.

The key attributes of CereMetrix include:

  • Unique, medical database for diagnosing complex brain-related disorders based on HD functional imagery and voxel level analysis
  • Provide a highly accurate, statistically valid standardized normative dataset for comparison and correlation of related symptomology
  • Proprietary software, scalable platform, with advanced intelligence and predicative analytics capabilities
  • Robust capabilities and easy to use
  • Accelerate accurate and effective diagnosis across the range of complex brain disorders
  • Enable appropriate diagnosis and treatment

About CereScan®

CereScan® combines state-of-the-art brain imaging technologies with a patient-centered model of care to provide the highest level of neuro-diagnostics available. CereScan utilizes state-of-the-art gamma camera technology, new generation imaging software and a proprietary process to produce comprehensive medical reports including voxel level images of brain function and physiology. Our functional brain imaging technologies are the most sophisticated in the world today. Additional information about the company is available at https://cerescan.com.

CereScan® and CereMetrix® are registered trademark of CereHealth Corp.

Contacts

RAM Communications
Ron Margulis, 908-272-3930
ron@rampr.com